Cover Image

Letter: Tenofovir Alafenamide—The “Star of Potential” for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	YaoYao Dai, JunFeng Zhu
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Letter: “Tenofovir Alafenamide—The ‘Star of Potential’ for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials.” Authors' Reply
by: Maria Buti
Published: (2025)

Letter on “Efficacy and Safety of Tenofovir Alafenamide ( TAF ) and Tenofovir Disoproxil Fumarate ( TDF ) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment”
by: Yan Liu, et al.
Published: (2025)

Tenofovir Alafenamide Therapy Throughout Pregnancy in Mothers With Hepatitis B
by: Xingfei Pan, et al.
Published: (2025)

Letters on “Efficacy and Safety of Tenofovir Alafenamide ( TAF ) and Tenofovir Disoproxil Fumarate ( TDF ) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment.” Authors' Reply
by: Grace Lai‐Hung Wong, et al.
Published: (2025)

Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment
by: Grace Lai‐Hung Wong, et al.
Published: (2025)

Letter: Reassessing Tenofovir Alafenamide Use Throughout Pregnancy—A New Horizon in Hepatitis B Therapy. Authors' Reply
by: Xingfei Pan, et al.
Published: (2025)

Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline–A Step Toward Functional Cure or a Marginal Margin?
by: Yao‐Chun Hsu, et al.
Published: (2026)

Superior Efficacy of Tenofovir Alafenamide Compared With Entecavir in Reducing Hepatitis B Surface Antigen: A Multicentre Propensity Score‐Matched Study Using Linear Mixed‐Effects Models
by: Takashi Kumada, et al.
Published: (2026)

Letter: Late Diagnosis of Chronic Hepatitis B—Quantifying the Missed Opportunities and Clinical Consequences
by: Bi‐Yu Gao, et al.
Published: (2025)

Letter: Assessing the Durability of Treatment Effects: Long‐Term Outcomes of ESWL and ERCP for Pancreatic Duct Stones in Chronic Pancreatitis
by: Wei‐Zhen Tang, et al.
Published: (2024)

Letter: Reconsidering Tenofovir Disoproxil Fumarate Use in Light of Emerging Safety Evidence
by: Priyadarshini Zula, et al.
Published: (2026)

Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’
by: Dong Hyun Kim, et al.
Published: (2025)

Letter on “Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China”
by: Ersel Bilgin, et al.
Published: (2025)

Editorial: HBeAg ‐Positive Chronic Hepatitis B With Low HBsAg Levels—Exploring Clinical Significance of preS2 Deletion Mutations
by: Ying‐Nan Tsai, et al.
Published: (2025)

Letter: Refining Mortality Estimates in Severe Alcohol‐Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment
by: Shupeng Zhao, et al.
Published: (2025)

Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’—Authors' Reply
by: Ning Yu, et al.
Published: (2025)

Letter: Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor
by: Shoko Miyahara, et al.
Published: (2025)

Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease
by: Qiong Yi, et al.
Published: (2024)

Letter: Advancing Serologic Classification in Indeterminate Chronic Hepatitis B Through Dynamic and Integrated Frameworks
by: Chun‐Chieh Chen, et al.
Published: (2025)

Letter on ‘Post‐TIPS Overt Hepatic Encephalopathy Increases Long‐Term but Not Short‐Term Mortality in Cirrhotic Patients With Variceal Bleeding: A Large‐Scale, Multicentre Real‐World’
by: Silvia Nardelli, et al.
Published: (2025)

Letter: Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor: Authors' Reply
by: Kee Huat Chuah, et al.
Published: (2025)

Letter: Advancing Serologic Classification in Indeterminate Chronic Hepatitis B Through Dynamic and Integrated Frameworks—Authors' Reply
by: Rui Huang, et al.
Published: (2025)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
by: Nina Dominik, et al.
Published: (2024)

Letter: Zinc and selenium—Potential biomarkers for chronic liver disease?
by: Zhuo Li, et al.
Published: (2024)

Letter on ‘Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis’: Authors' Reply
by: Lukas Burghart, et al.
Published: (2026)

Letter on “Immigration Factors and Monitoring of Chronic Hepatitis B Infection Among Foreign‐Born: The FOCUS‐HBV Multicentre Cohort”
by: Dong Hyun Kim, et al.
Published: (2025)

Clinical Course and Prognosis of Long‐Term Survivors of Hepatocellular Carcinoma
by: Soon Sun Kim, et al.
Published: (2025)

Letter: Trajectories of Hepatic Function Markers Enable Early Prediction of Hepatic Recompensation
by: Benedikt Silvester Hofer, et al.
Published: (2026)

Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis
by: Silvio Danese, et al.
Published: (2025)

Post‐TIPS Overt Hepatic Encephalopathy Increases Long‐Term but Not Short‐Term Mortality in Cirrhotic Patients With Variceal Bleeding: A Large‐Scale, Multicenter Real‐World Study
by: Yi Xiang, et al.
Published: (2025)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis
by: Ewan Forrest, et al.
Published: (2025)

Clinical Trial: Hepatitis B Virus Genotype and a Combination of End‐of‐Treatment Biomarkers Predict Severe Flares After Nucleos(t)ide Analogue Cessation
by: Arno Furquim d’Almeida, et al.
Published: (2025)

Letter: ‘Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study’
by: Matthias Kelm, et al.
Published: (2025)

Letter on ‘Unveiling Drug‐Induced Autoimmune‐Like Hepatitis in Autoimmune Hepatitis Patients: A Multicenter Retrospective Study’
by: Muhammad Ibrahim Khalil, et al.
Published: (2025)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
by: Francisco Idalsoaga, et al.
Published: (2025)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors—Authors' Reply
by: Ying‐Nan Tsai, et al.
Published: (2025)

Letter: Addressing Gaps in Hospital‐Based Hepatitis C Screening—Insights and Recommendations
by: Zhen Deng, et al.
Published: (2025)

Clinical Trial: Immunogenicity of Double‐Dose Versus Standard‐Dose of Hepatitis B Virus Vaccine in Inflammatory Bowel Disease
by: Anupam Kumar Singh, et al.
Published: (2025)

Letter: The Prognostic Role of IGF‐1 in Chronic Liver Disease
by: Muhammad Osama, et al.
Published: (2024)

Letter: Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study: Authors' Reply
by: Nathan Grellier, et al.
Published: (2025)